---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-084911"
form_type: "8-K"
ticker: "TVRD"
cik: "0001346830"
company_name: "Tvardi Therapeutics, Inc."
filed_at: "2024-08-01T23:59:59+00:00"
generated_at: "2026-05-31T13:42:47.560242+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cara Therapeutics gets Nasdaq extension to Jan 2025 to regain $1 bid price; stock moved to Capital Market

## Summary
- Nasdaq granted 180-day extension, until January 27, 2025, to meet minimum $1.00 closing bid price for 10 consecutive business days.
- Company's common stock transferred from Nasdaq Global Market to Nasdaq Capital Market effective August 1, 2024.
- If compliance not achieved by deadline, Nasdaq will delist; company may appeal to a Nasdaq Hearings Panel.
- Company will monitor bid price and consider options including a reverse stock split to regain compliance.

## SEC filing metadata
- accession: 0001104659-24-084911
- form_type: 8-K
- ticker: TVRD
- cik: 0001346830
- company_name: Tvardi Therapeutics, Inc.
- filed_at: 2024-08-01T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1346830/000110465924084911/0001104659-24-084911-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1346830/000110465924084911/tm2420653d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-084911
- JSON: https://secwatch.observer/filing/0001104659-24-084911.json
- Plain text: https://secwatch.observer/filing/0001104659-24-084911.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.